{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:56:55Z","timestamp":1790719015511,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06816-0","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:25:26Z","timestamp":1790670326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the PSMA PET\/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation"],"prefix":"10.1007","volume":"44","author":[{"given":"J.","family":"G\u00f3mez Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fern\u00e1ndez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"6816_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"6816_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Thomson A, Chen DC et al (2025) The role of prostate-specific membrane antigen positron emission tomography for assessment of local recurrence and distant metastases in patients with biochemical recurrence of prostate cancer after definitive treatment: a systematic review and meta-analysis. Eur Urol 88:129\u2013141. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.006","journal-title":"Eur Urol"},{"key":"6816_CR3","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1007\/s00259-025-07292-1","volume":"52","author":"C Burgard","year":"2025","unstructured":"Burgard C, Frei M, Blickle A et al (2025) PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009<\u2009=\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. Eur J Nucl Med Mol Imaging 52:4368\u20134376. https:\/\/doi.org\/10.1007\/s00259-025-07292-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6816_CR4","volume-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","author":"European Association of Urology","year":"2026","unstructured":"European Association of Urology (2026) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, 2026 edn. EAU Guidelines Office, Arnhem, The Netherlands. https:\/\/uroweb.org\/guidelines\/prostate-cancer Accessed 9 September 2026","edition":"2026"},{"key":"6816_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M et al (2023) PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50:1466\u20131486. https:\/\/doi.org\/10.1007\/s00259-022-06089-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6816_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.07.007","author":"A Peyrottes","year":"2026","unstructured":"Peyrottes A, Turpin L, Fern\u00e1ndez Hern\u00e1ndez L, G\u00f3mez Rivas J, Roupr\u00eat M (2026) PSMA PET in prostate cancer: clinical value, access challenges, and priorities for implementation. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.07.007","journal-title":"Eur Urol Oncol"},{"key":"6816_CR7","unstructured":"de Sanidad M, Gobierno de Espa\u00f1a (2026) BIFIMED: buscador de la informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor de julio 2026. Accessed 9 September 2026. https:\/\/www.sanidad.gob.es\/va\/profesionales\/medicamentos.do?cn=763308&metodo=verDetalle"},{"key":"6816_CR8","unstructured":"European Medicines Agency (2026) Pylclari, INN-piflufolastat (18F): EPAR and product information. Updated 2 March 2026. Accessed 9 September 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pylclari"},{"key":"6816_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2967\/jnumed.125.271344","volume":"67","author":"P Krausewitz","year":"2026","unstructured":"Krausewitz P, Essler M, Gaertner FC et al (2026) Impact of initial prostate-specific membrane antigen PET\/CT staging and prostate-specific membrane antigen-targeted biopsy on treatment decisions in prostate cancer: results from the phase 2 DEPROMP trial. J Nucl Med 67:60\u201366. https:\/\/doi.org\/10.2967\/jnumed.125.271344","journal-title":"J Nucl Med"},{"key":"6816_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euros.2025.03.007","volume":"75","author":"DE Oprea-Lager","year":"2025","unstructured":"Oprea-Lager DE, van Elst T, Aluwini S et al (2025) How does routine prostate-specific membrane antigen positron emission tomography\/computed tomography modify the current management of prostate cancer? A multidisciplinary view. Eur Urol Open Sci 75:69\u201379. https:\/\/doi.org\/10.1016\/j.euros.2025.03.007","journal-title":"Eur Urol Open Sci"},{"key":"6816_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/medicina61050924","volume":"61","author":"J G\u00f3mez Rivas","year":"2025","unstructured":"G\u00f3mez Rivas J, de la Parra I, Infante S et al (2025) Prostate-specific membrane antigen positron emission tomography (PSMA-PET) in initial staging of prostate cancer patients: the beginning of a new era. Med (Kaunas) 61:924. https:\/\/doi.org\/10.3390\/medicina61050924","journal-title":"Med (Kaunas)"},{"key":"6816_CR12","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M et al (2023) Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 50:2830\u20132845. https:\/\/doi.org\/10.1007\/s00259-023-06255-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6816_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T et al (2021) Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol 79:413\u2013418. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.043","journal-title":"Eur Urol"},{"key":"6816_CR14","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","volume":"50","author":"A Holzgreve","year":"2023","unstructured":"Holzgreve A, Unterrainer M, Calais J et al (2023) Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging 50:3750\u20133754. https:\/\/doi.org\/10.1007\/s00259-023-06332-y","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:01:29Z","timestamp":1790715689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6816"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06816-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"9 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, an artificial intelligence-based tool (ChatGPT, OpenAI) was used to assist with language editing, clarity, and formatting. The authors reviewed and verified all AI-assisted modifications and remain fully responsible for the content, scientific accuracy, interpretation, and conclusions of the manuscript.","order":4,"name":"Ethics","label":"AI-assisted language editing","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"717"}}